-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Ebfnk4Ron/67l9qnE/1vLBOo2t8FR5572+kB/ItsvGTgKRFvjDNuWAjsx+5yqshy ZDKFWo12kus1AU+W6sxU+A== 0001230295-07-000269.txt : 20070403 0001230295-07-000269.hdr.sgml : 20070403 20070403160310 ACCESSION NUMBER: 0001230295-07-000269 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20070330 FILED AS OF DATE: 20070403 DATE AS OF CHANGE: 20070403 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: JAEGER STEPHEN O CENTRAL INDEX KEY: 0001243960 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15313 FILM NUMBER: 07744351 MAIL ADDRESS: STREET 1: 11 TOPSTONE ROAD CITY: REDDING STATE: CT ZIP: 06896 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SAVIENT PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000722104 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 133033811 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 BUSINESS PHONE: 7324189300 MAIL ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 FORMER COMPANY: FORMER CONFORMED NAME: BIO TECHNOLOGY GENERAL CORP DATE OF NAME CHANGE: 19920703 4 1 jae174.xml X0202 4 2007-03-30 0 0000722104 SAVIENT PHARMACEUTICALS INC SVNT 0001243960 JAEGER STEPHEN O C/O SAVIENT PHARMACEUTICALS, INC ONE TOWER CENTER BLVD., 14TH FLOOR EAST BRUNSWICK NJ 08816 1 0 0 0 Common Stock, $.01 par value per share 2007-03-30 4 A 0 665 12.0200 A 24320.0000 D Option to Purchase Common Stock, $.01 par value 12.0200 2007-03-30 4 A 0 10000 12.0200 A 2008-03-30 2017-03-30 Common Stock, $.01 par value per share 10000.0000 10000.0000 D These shares were granted pursuant to the Company's 2004 Incentive Plan, which provides for the grant to non-executive Chairperson of that number of shares of Common Stock having an aggregate fair market value on the last business day of each quarter up to $8,000.00, until he is no longer a non-executive Chairperson. On March 30, 2007, the fair market value of the Common Stock, based, on the closing price, was $12.02. These options will become fully vested and immediately exercisable on 3/30/08. By: /s/ Michelle Zelinski as Attorney-In-Fact for 2007-04-03 -----END PRIVACY-ENHANCED MESSAGE-----